Reviewer’s report

Title: Bone turnover is adequately suppressed in osteoporotic patients treated with Bisphosphonates in daily practice

Version: 3 Date: 18 April 2011

Reviewer: Michael McClung

Reviewer’s report:

Thank you for addressing/answering previous questions. I suggest these additional changes:

Minor Essential Revisions

1. In Background section, have first sentence of 3rd paragraph read “…that represents a statistically significant change)…”

2. In Methods section:
   a. Change zoledronate to zoledronic acid
   b. State whether the each of paired samples collected in Group 1 were measured in same or different assays

3. In 1st sentence under “Least Significant Change …: heading read “The LSC was calculated with the formula …, where AV represents the analytical change in our laboratory …”

4. In several sections, change “t-score” to “T-score”

5. In last paragraph of Results, correct the spelling of “cholecalciferol”

Discretionary Revisions

1. In Table 1, remove rows with BMD – since reporting both BMD and T-scores is redundant.

2. Add a new table (to be Table 3 while current Table 3 becomes Table 4) to clarify the comment made in last paragraph of Results about proportion of patients in Group 2 with values in the lower half of the premenopausal range. Use data from baseline and followup values from Group 1 for the new table.

New Table: Distribution of Marker Values Compared to Reference Range Before and On Bisphosphonate Therapy
Compared to Premenopausal Reference Range (% of Patients) CTX P1NP
Baseline Follow-up Baseline Follow-up
  Below
  Lower half
  Upper half
  Above

**Level of interest:** An article whose findings are important to those with closely related research interests

**Quality of written English:** Needs some language corrections before being published

**Statistical review:** No, the manuscript does not need to be seen by a statistician.

**Declaration of competing interests:**

In the past 5 years, I have received research grants, consulting fees and honorarium from Amgen, GSK, Lilly, Merck, Novartis, Procter and Gamble, sanofi-aventis, Roche, and Warner-Chilcott